Pharmacogenomic polygenic risk score for clopidogrel responsiveness among Caribbean Hispanics: A candidate gene approach
J Duconge, E Santiago… - Clinical and …, 2021 - Wiley Online Library
This multicenter clinical study was aimed at conducting a targeted pharmacogenomic
association analysis of residual on‐clopidogrel platelet reactivity in 474 Caribbean Hispanic …
association analysis of residual on‐clopidogrel platelet reactivity in 474 Caribbean Hispanic …
Pharmacogenetic association study on clopidogrel response in Puerto Rican Hispanics with cardiovascular disease: a novel characterization of a Caribbean …
DF Hernandez-Suarez, MR Botton… - Pharmacogenomics …, 2018 - Taylor & Francis
Introduction High on-treatment platelet reactivity (HTPR) to clopidogrel imparts an increased
risk for ischemic events in adults with coronary artery disease. Platelet reactivity varies with …
risk for ischemic events in adults with coronary artery disease. Platelet reactivity varies with …
Genomewide association study of platelet reactivity and cardiovascular response in patients treated with clopidogrel: a study by the international clopidogrel …
Antiplatelet response to clopidogrel shows wide variation, and poor response is correlated
with adverse clinical outcomes. CYP2C19 loss‐of‐function alleles play an important role in …
with adverse clinical outcomes. CYP2C19 loss‐of‐function alleles play an important role in …
Genome-wide and candidate gene approaches of clopidogrel efficacy using pharmacodynamic and clinical end points—Rationale and design of the International …
Rationale The P2Y 12 receptor inhibitor clopidogrel is widely used in patients with acute
coronary syndrome, percutaneous coronary intervention, or ischemic stroke. Platelet …
coronary syndrome, percutaneous coronary intervention, or ischemic stroke. Platelet …
Pharmacogenomic polygenic response score predicts ischaemic events and cardiovascular mortality in clopidogrel-treated patients
JP Lewis, JD Backman, JL Reny… - European Heart …, 2020 - academic.oup.com
Aims Clopidogrel is prescribed for the prevention of atherothrombotic events. While
investigations have identified genetic determinants of inter-individual variability in on …
investigations have identified genetic determinants of inter-individual variability in on …
Clopidogrel pharmacogenetics: Beyond candidate genes and genome‐wide association studies
JP Lewis, AR Shuldiner - Clinical Pharmacology & …, 2017 - Wiley Online Library
While it is well established that genetic variation is a significant contributor to interindividual
variability in clopidogrel efficacy, candidate gene and genome‐wide approaches have failed …
variability in clopidogrel efficacy, candidate gene and genome‐wide approaches have failed …
Clinical implications of genetic admixture in Hispanic Puerto Ricans: impact on the pharmacogenetics of CYP2C19 and PON1
J Duconge, O Escalera, M Korchela… - Clinical Applications of …, 2012 - books.google.com
Antiplatelet therapy with clopidogrel (Plavix®) is now considered a cornerstone of
cardiovascular medicine. Clopidogrel resistance is an emerging clinical entity with …
cardiovascular medicine. Clopidogrel resistance is an emerging clinical entity with …
Genome-wide analysis of clopidogrel active metabolite levels identifies novel variants that influence antiplatelet response
JD Backman, JR O'Connell, K Tanner… - Pharmacogenetics …, 2017 - journals.lww.com
Clopidogrel is one of the most commonly used therapeutics for the secondary prevention of
cardiovascular events in patients with acute coronary syndromes. However, considerable …
cardiovascular events in patients with acute coronary syndromes. However, considerable …
Genetic and nongenetic factors affecting clopidogrel response in the Egyptian population
BM Khalil, MH Shahin, MHM Solayman… - Clinical and …, 2016 - Wiley Online Library
Aspirin and clopidogrel are the mainstay oral antiplatelet regimens, yet a substantial number
of major adverse cardiac events (MACE) still occur. Herein, we investigated genetic and …
of major adverse cardiac events (MACE) still occur. Herein, we investigated genetic and …
First pharmacogenomic analysis using whole exome sequencing to identify novel genetic determinants of clopidogrel response variability: results of the genotype …
MJ Price, AR Carson, SS Murray, T Phillips… - Journal of the American …, 2012 - jacc.org
Background Although on-treatment reactivity (OTR) while receiving clopidogrel is strongly
associated with CYP2C19 genotype, the majority of the hereditability in clopidogrel …
associated with CYP2C19 genotype, the majority of the hereditability in clopidogrel …